Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Overview
CoChat Summary
TL;DR
An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.
Key findings
- For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
- For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
- TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
- In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).
Methods
- Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
- Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
- Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.
Limitations
- The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
- The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
- Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
In type 1 diabetes, the Results (Table 2; page unavailable) show weaker correlations for hypoglycemia and glycemic variability than for mean glucose at 15 days. But they also show that both correlations increase as sampling extends from 3 to 15 days, contrary to the citing sentence’s claim that an increase with longer sampling has not been shown. The paper does not frame this analysis as >70% CGM use over 14 days. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that correlations with the full three-month data increased as sampling lengthened for both hypoglycemia and glycemic variability. From 3 to 15 days, r² rose from 0.32 to 0.66 for values ≤70 mg/dL and from 0.36 to 0.70 for coefficient of variation—the opposite of the attributed claim. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The first longitudinal CGM data demonstrated a 13percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61).”
What the sources say
- Disputedcites [61] 62. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med. 2016;375(7):644-654. sourceExperimental — accuracy not yet measured
The Study Outcomes report different CGM time-in-range results: 59.5% to 74.7% overnight and 56.8% to 66.3% over 24 hours with closed-loop therapy. The paper defines its target range as 63–140 mg/dL, not 70–140 mg/dL; it does not report the claimed increase from 43% to 56%. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Partly supportedcites [2] 2. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 2017;40(4):538-545. sourceExperimental — accuracy not yet measured
The Introduction reports that several randomized trials found CGM benefits, including reduced HbA1c and hypoglycemia, particularly in adults with type 1 diabetes. But the Conclusions say this trial included only insulin-pump users; extending its results to people using injections is described as reasonable, not demonstrated. The paper therefore does not establish benefits regardless of insulin delivery method or across all people with diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Not checked — no full text of the sourcecites [5] 5. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, for the DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017; 40:736-741. source
- Supportedcites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. source
The Discussion reports significant glycemic benefits from real-time CGM that were comparable with pump (CSII) and injection (MDI) therapy. The study concerns people with type 1 diabetes. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [7] 7. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, openlabel, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893-902. source
- Not checked — no full text of the sourcecites [8] 8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263. source
- Partly supportedcites [9] 9. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulintreated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. sourceExperimental — accuracy not yet measured
The Results report significant reductions in hypoglycemic events with flash glucose monitoring in adults with insulin-treated type 2 diabetes, supporting a clinical benefit. The Results also state that 95% of participants used an insulin pen or syringe and 5% used continuous subcutaneous insulin infusion; the paper does not establish that the benefit held regardless of insulin delivery method. No page numbers are available in our copy. (LLM, conf=0.85)
- Partly supportedcites [10] 10. Choudhary P, Olsen BS, Conget I, et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18(5):288-291. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the CGM-based MiniMed 640G pump system can help patients with type 1 diabetes avoid hypoglycemia. But this short, uncontrolled study examined a predictive pump-suspension system, not CGM use regardless of insulin delivery method; it does not establish a benefit across delivery methods or isolate the benefit of CGM itself. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Could not verifycites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. sourceExperimental — accuracy not yet measured
The Prespecified outcomes section (page unavailable) identifies HbA1c as this type 1 diabetes study’s primary endpoint. Neither that section nor the Discussion passages establish that A1C is the key surrogate marker for long-term complications in people with both type 1 and type 2 diabetes. Searches for that surrogate-marker relationship and for complications found no passage stating it. (LLM, conf=0.72)
- Partly supportedcites [33] 32. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55(12):3155-3162. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links near-normal glycaemia with reduced complication risk in type 1 diabetes, and Methods > Outcome measure (page unavailable) uses HbA1c as this trial’s primary endpoint. The paper does not establish HbA1c as the key surrogate marker for long-term complications in both type 1 and type 2 diabetes. (LLM, conf=0.81)
- Could not verifycites [32] 31. Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. Diabetes Care 2017;40:655 ʹ 662. sourceExperimental — accuracy not yet measured
The Baseline Assessment section says HbA1c was measured at the start of monitoring, but does not describe it as a surrogate marker for long-term complications. The Research Design and Methods section examines arrhythmias during hypoglycemia, not A1C as a primary endpoint in CGM studies. Searches for the surrogate-marker and primary-endpoint claims found no supporting passage in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 16 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the advent of newer studies of CGM in noninsulin‐treated individuals and increasing uptake, the utility of CGM is progressively being endorsed in this population.”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycaemia is associated with an increased risk of vascular events, explaining recent consensus advocating hypoglycaemic exposure at <1% (i.e.<15 min/day) in individuals at high CV risk.137,138”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering the older age of participants and comorbid conditions reported, the mean HbA1c, GMI, TIR, and TBR results (8.0%, 7.6%, 56%, and 1.0% at 6 months, respectively) demonstrate close adherence to established glycemic targets (23, 24, 38).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [193]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ FIGURES / TABLES · p. 4
“2 Figures / 3 Tables”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Time in Ranges · p. 11
“Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Cited by
Items 401–500 of 3,959
Potier, L., Hansel, B., Larger, É., Gautier, J., Carreira, D., Assemien, R., Lantieri, O., Riveline, J., & Roussel, R. (2020) · Diabetes Care · doi:10.2337/dc20-2019 · Cited by 44
Haidar, A., Yale, J., Lovblom, L. E., Cardinez, N., Orszag, A., Falappa, C. M., Gouchie‐Provencher, N., Tsoukas, M. A., El Fathi, A., Rene, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14335 · Cited by 42
“Secondary outcomes included time spent in, below and above the target range, glucose variability and insulin delivery.(28,29) Outcomes were calculated using sensor readings.”
MethodBerge, T. V. D., Remus, K., Biester, S., Reschke, F., Klusmeier, B., Adolph, K., Holtdirk, A., Thomas, A., Kordonouri, O., Danne, T., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14706 · Cited by 47
“CGM data were evaluated according to the Advanced Technologies and Treatments for Diabetes (ATTD) consensus and target recommendations.(12,13)”
MethodSelf-citationHaidar, A., Lovblom, L. E., Cardinez, N., Gouchie‐Provencher, N., Orszag, A., Tsoukas, M. A., Falappa, C. M., Jafar, A., Ghanbari, M., Eldelekli, D., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01805-3 · Cited by 48
Montaser, E., Fabris, C., & Kovatchev, B. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0104 · Cited by 41
“40 In the case of treatment directed by a health care provider, this optimization is based on review of an AGP and associated metrics 15 ; in the case of AID, it is driven by the control algorithm cost function.”
InfluentialSelf-citationInsulin: evolution of insulin formulations and their application in clinical practice over 100 years
Bolli, G. B., CHENG, A. Y. Y., & Owens, D. R. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01938-4 · Cited by 58
Continuous Glucose Monitoring for Prediabetes: What Are the Best Metrics?
Zahalka, S. J., Galindo, R. J., Shah, V. N., & Wang, C. C. L. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241242487 · Cited by 232
“Each 5% increment in time spent in the target range 70 to 180 mg/dl is extrapolated to correlate with a reduction in A1c by 0.4%, 21 which is associated with clinically significant benefits for individuals with type 1 diabetes mellitus and T2DM.20 For GV, the consensus statement established a goal for the CV for those…”
InfluentialDavis, G. M., Hughes, M. S., Brown, S. A., Sibayan, J., Perez-Guzman, M. C., Stumpf, M., Thompson, Z., Basina, M., Patel, R. M., Hester, J., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0304 · Cited by 41
Self-citationWright, E. E., Morgan, K., Fu, D. K., Wilkins, N., & Guffey, W. J. (2020) · Clinical Diabetes · doi:10.2337/cd20-0042 · Cited by 40
“Primary care providers treat the vast majority of patients with type 2 diabetes, and the target ranges and time goals defined for these patients are as follows (35):”
BackgroundAvari, P., Uduku, C., George, D., Herrero, P., Reddy, M., & Oliver, N. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0276 · Cited by 40
Chesser, H., Srinivasan, S., Puckett, C., Gitelman, S. E., & Wong, J. C. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221139873 · Cited by 40
“29,30 Validated pre-intervention and post-intervention surveys included physical activity questionnaires, 31 the Dietary Screener Questionnaire, 32 Problem Areas in Diabetes for teenagers (PAID-T) to assess diabetes distress, 33 and the Pediatric Quality of Life inventory (PedsQL) which is…”
Bionic Pancreas Research Group, Beck, R. W., Russell, S. J., Damiano, E. R., El-Khatib, F. H., Ruedy, K. J., Balliro, C., Li, Z., & Calhoun, P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0167 · Cited by 40
Self-citationGlycemic variability: Importance, relationship with physical activity, and the influence of exercise
Sparks, J. R., Kishman, E. E., Sarzynski, M. A., Davis, J. M., Grandjean, P. W., Durstine, J. L., & Wang, X. (2021) · Sports Medicine and Health Science · doi:10.1016/j.smhs.2021.09.004 · Cited by 51
2022 National Standards for Diabetes Self-Management Education and Support
Davis, J., Fischl, A. H., Beck, J. K., Browning, L., Carter, A., Condon, J. E., Dennison, M., Francis, T., Hughes, P. J., Jaime, S., et al. (2022) · Diabetes Spectrum · doi:10.2337/ds22-ps02 · Cited by 50
Assessment of glycemia in chronic kidney disease
Hassanein, M., & Shafi, T. (2022) · BMC Medicine · doi:10.1186/s12916-022-02316-1 · Cited by 49
“The main goal of using CGM for glycemic monitoring is to maximize the TIR while minimizing time above or time below target [72].”
BackgroundMethodLombardo, F., Passanisi, S., Alibrandi, A., Bombaci, B., Bonfanti, R., Delvecchio, M., Candia, F. D., Mozzillo, E., Piccinno, E., Piona, C. A., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0491 · Cited by 43
Bergenstal, R. M., HACHMANN-NIELSEN, E., Kvist, K., Peters, A. L., Tarp, J. M., & Buse, J. B. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0447 · Cited by 46
Self-citationReal-World Evidence Analysis of a Hybrid Closed-Loop System
Alwan, H., Wilinska, M. E., Ruan, Y., Silva, J. D., & Hovorka, R. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231185348 · Cited by 43
Self-citationCichosz, S. L., Jensen, M. H., & Olesen, S. S. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0532 · Cited by 45
Renard, É., Weinstock, R. S., Aleppo, G., Bode, B. W., Brown, S. A., CASTORINO, K. N., Hirsch, I. B., Kipnes, M. S., Laffel, L. M., Lal, R., et al. (2024) · Diabetes Care · doi:10.2337/dc24-1550 · Cited by 46
Self-citationReal-World Data from the First U.S. Commercial Users of an Implantable Continuous Glucose Sensor
Sanchez, P., Ghosh-Dastidar, S., Tweden, K. S., & Kaufman, F. R. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0234 · Cited by 40
“…real-world setting since its commercial release, the target of 4% or less time in hypoglycemia ( < 70 mg/dL) recommended by Battelino et al. 13 was nearly achieved and the TIR has exceeded some prior reports of < 60% for a CGM system not coupled to an algorithm to automate insulin delivery.”
Lee, C.-L., Chen, C.-H., Wu, M.-J., & Tsai, S.-F. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319898370 · Cited by 40
Musacchio, N., Giancaterini, A., Guaita, G., Ozzello, A., Pellegrini, M. A., Ponzani, P., Russo, G. T., Zilich, R., & Micheli, A. D. (2020) · Journal of Medical Internet Research · doi:10.2196/16922 · Cited by 53
“Currently, thanks to the technological evolution, these data can be transmitted automatically from the glucometers via “cloud” or on data integration platforms that collect elements from different devices and provide standardized reports [11,12].”
BackgroundPractical implementation of automated closed-loop insulin delivery: A French position statement
Tubiana‐Rufi, N., Schaepelynck, P., Franc, S., Chaillous, L., Joubert, M., Renard, É., Reznik, Y., Abettan, C., Bismuth, É., Beltrand, J., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.10.004 · Cited by 44
Lin, Y. K., Richardson, C. R., Dobrin, I., DeJonckheere, M. J., Mizokami-Stout, K., Fetters, M. D., Aikens, J. E., Fisher, S. J., Ye, W., & Pop-Busui, R. (2022) · Diabetes Care · doi:10.2337/dc21-1285 · Cited by 40
“CGM glucose measures (20), including the percentage of time spent with glucose levels >180 and >250 mg/dL and <70 and <54 (50 for Medtronic CGMs) mg/dL and percentage of time in range (glucose levels between 70 and 180 mg/dL (20)), glucose variability, and CGM alarm settings, including hypoglycemia alarm (on/off), pre…”
BackgroundInfluentialvan Veldhuisen, C. L., Latenstein, A. E. J., Blauw, H., Vlaskamp, L. B., Klaassen, M., Lips, D. J., Bonsing, B. A., van der Harst, E., Stommel, M. W. J., Bruno, M. J., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2022.3702 · Cited by 51
Self-citationFlatt, A. J., Peleckis, A. J., Dalton-Bakes, C., Nguyen, H.-L., Ilany, S., Matus, A., Malone, S. K., Goel, N., Jang, S., Weimer, J., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0506 · Cited by 39
“Nevertheless, from 3 months onward, the median percentage of time-in-range (70–180 mg/dL) exceeded the consensus target of 70%, well above the target of >50% recommended in those at high risk of severe hypoglycemia.(49) This change was predominantly driven by the early improvement in hypoglycemia avoidance on AID inte…”
Significance of Glycemic Variability in Diabetes Mellitus
Kusunoki, Y., Konishi, K., Tsunoda, T., & Koyama, H. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8424-21 · Cited by 40
“Therefore, CGM may be considered for GV suppression in both T 1DM and T2DM.”
BackgroundMethodInfluentialPolsky, S., Buschur, E., Dungan, K., Garcetti, R., Nease, E., Malecha, E., Bartholomew, A., Johnson, C., Pyle, L., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0012 · Cited by 39
“In the third trimester, the mean sensor glucose was higher with HCL (119 [4] mg/dL SAPT vs. 132 [4] mg/dL HCL, P = 0.0475).”
InfluentialPrabhu Navis, J., Leelarathna, L., Mubita, W., Urwin, A., Rutter, M. K., Schofield, J., & Thabit, H. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01614-5 · Cited by 39
Glucose measurement in body fluids: A ready reckoner for clinicians
Kubihal, S., Goyal, A., Gupta, Y., & Khadgawat, R. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.021 · Cited by 47
Parent, C., Lespagnol, É., Berthoin, S., Tagougui, S., Heyman, J., Stuckens, C., Gueorguieva, I., Balestra, C., Tonoli, C., Kozon, B., et al. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.10.006 · Cited by 54
Piona, C. A., Marigliano, M., Roncarà, C., Mozzillo, E., Candia, F. D., Zanfardino, A., Iafusco, D., Maltoni, G., Zucchini, S., Piccinno, E., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0040 · Cited by 41
Passanisi, S., Salzano, G., Bombaci, B., Minuto, N., Bassi, M., Bonfanti, R., Scialabba, F., Mozzillo, E., Candia, F. D., Monti, S. M., et al. (2024) · Diabetes Care · doi:10.2337/dc23-2311 · Cited by 48
Preventing diabetes complications
Templer, S., Abdo, S., & Wong, T. (2024) · Internal Medicine Journal · doi:10.1111/imj.16455 · Cited by 59
Lin, Y. K., Groat, D., Chan, O., Hung, M., Sharma, A., Varner, M. W., Gouripeddi, R., Facelli, J. C., & Fisher, S. J. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz005 · Cited by 39
“A recent international consensus [10] further proposed to target on the glucose time-in-range (defined as the time percentage with glucose levels between 70–180 mg/ dL) by reducing the time in hypo/hyperglycemia.”
BackgroundIntermittent Use of Continuous Glucose Monitoring: Expanding the Clinical Value of CGM
Ziegler, R., Heinemann, L., Freckmann, G., Schnell, O., Hinzmann, R., & Kulzer, B. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820905577 · Cited by 39
Self-citationCharleer, S., De Block, C., Nobels, F., Radermecker, R. P., Lowyck, I., Mullens, A., Scarnière, D., Spincemaille, K., Strivay, M., Weber, E., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1531 · Cited by 39
Self-citationEfficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown
Boscari, F., Ferretto, S., Uliana, A., Avogaro, A., & Bruttomesso, D. (2021) · Nutrition & Diabetes · doi:10.1038/s41387-020-00147-8 · Cited by 39
Dillmann, C., Amoura, L., Fall-Mostaine, F., Coste, A., Bounyar, L., & Kessler, L. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821994586 · Cited by 44
Nørgaard, S. K., Mathiesen, E. R., Nørgaard, K., & Ringholm, L. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0109 · Cited by 38
“13 The standard deviation (SD) and the coefficient of variance (CV) were explored as well.”
InfluentialSelf-citationBoureau, A., Guyomarch, B., Gourdy, P., Allix, I., Annweiler, C., Cervantes, N., Chapelet, G., Delabrière, I., Guyonnet, S., Litke, R. R., et al. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18341 · Cited by 45
Friedman, J. G., Cardona, Z., Szmuilowicz, E. D., & Aleppo, G. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s374663 · Cited by 60
Dovč, K., Bergford, S., Fröhlich-Reiterer, E. E., Zaharieva, D. P., Potočnik, N., Müller, A., Lenarčič, Ž., Calhoun, P. M., Fritsch, M., Sourij, H., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0178 · Cited by 44
“9,10 Part of the challenge with current AID technology is due to the pharmacokinetic and pharmacodynamic delay, and comparatively slow absorption time from the subcutaneous administration of insulin.”
Self-citationReal‐world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta‐analysis
Yang, Q., Zeng, B., Hao, J., Yang, Q., & Sun, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15718 · Cited by 46
Lin, Y. K., Groat, D., Chan, O. T. M., Hung, M., Sharma, A. R., Varner, M. W., Gouripeddi, R., Facelli, J. C., & Fisher, S. J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0016 · Cited by 38
New and Emerging Technologies in Type 1 Diabetes
Sherwood, J. S., Russell, S. J., & Putman, M. S. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.07.006 · Cited by 49
Schlüter, S., Freckmann, G., Heinemann, L., Wintergerst, P., & Lange, K. (2020) · Diabetic Medicine · doi:10.1111/dme.14467 · Cited by 43
Self-citationBomholt, T., Adrian, T., Nørgaard, K., Ranjan, A. G., Almdal, T., Larsson, A. O., Vadstrup, M., Rix, M., Feldt‐Rasmussen, B., & Hornum, M. (2020) · The Nephron journals/Nephron journals · doi:10.1159/000511614 · Cited by 40
Self-citationO’Malley, G., Özaslan, B., Levy, C. J., CASTORINO, K. N., Desjardins, D., Levister, C. M., MCCRADY-SPITZER, S. K., Church, M. M., Kaur, R. J., Reid, C. L., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0112 · Cited by 44
Self-citationAroda, V. R., & Eckel, R. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14830 · Cited by 43
“emphasis on reducing hypoglycaemia and less emphasis on maintaining target glucose levels.(122)”
BackgroundSpartano, N. L., Sultana, N., Lin, H., Cheng, H., Lu, S., Fei, D., Murabito, J. M., Walker, M. E., Wolpert, H. A., & Steenkamp, D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae626 · Cited by 57
Mukhopadhyay, A., Sumner, J., Ling, L. H., Quek, R. H. C., Tan, A. T. H., Teng, G. G., Seetharaman, S. K., Gollamudi, S. P. K., Ho, D., & Motani, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19158979 · Cited by 38
Layne, J. E., Jepson, L. H., Carite, A. M., Parkin, C. G., & Bergenstal, R. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0197 · Cited by 37
Self-citationGomez-Peralta, F., Abreu, C., Fernández-Rubio, E., Cotovad, L., Pujante, P., Gaztambide, S., Bellido, D., Menéndez Torre, E., Ruiz-Valdepeñas, S., Bello, H., et al. (2023) · Diabetes Care · doi:10.2337/dc22-0525 · Cited by 36
“0 mmol/L) (2) (primary objective), glucose management indicator (GMI), time above range (TAR), time below range, mean amplitude of glycemic excursions, SD, coefficient of variation, high blood glucose index (HGBI), and low blood glucose index.”
BackgroundKlarskov, C. K., Windum, N. A., Olsen, M. T., Dungu, A. M., Jensen, A. K., Lindegaard, B., Pedersen‐Bjergaard, U., & Kristensen, P. L. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0291 · Cited by 40
“The primary endpoint was time in range (TIR), defined according to international standards for outpatients 13 and measured as the percentage of time per day within glucose range of 3.9–10.0 mmol/L (70–180 mg/dL).”
InfluentialScully, K. J., Palani, G., Zheng, H., Moheet, A., & Putman, M. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0354 · Cited by 37
Bellido, V., Aguilera, E., Cardona‐Hernandez, R., Díaz-Soto, G., de Villar, N. G. P., César, M. J. P., & Ampudia‐Blasco, F. J. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221088601 · Cited by 47
Dave, D., Vyas, K., Branan, K. L., McKay, S. V., DeSalvo, D. J., Gutiérrez‐Osuna, R., Coté, G. L., & Erraguntla, M. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221116393 · Cited by 47
Reddy, M., & Oliver, N. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15504 · Cited by 47
Toh, D. W. K., Fu, A. S., Mehta, K. A., Lam, N. Y. L., Haldar, S., & Henry, C. J. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.04.006 · Cited by 40
A comprehensive review of non-invasive optical and microwave biosensors for glucose monitoring
Martins, A. J. L., Velásquez, R., Gaillac, D. B., dos Santos, V. N., Tami, D., Souza, R. N. P., Osorio, F. C., Fogli, G. A., Soares, B. S., do Rego, C. G., et al. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.117081 · Cited by 49
Özer, K., Cooper, A. M., Ahn, L. P., Waggonner, C. R., & Blevins, T. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0500 · Cited by 38
Time-in-range as a target in type 2 diabetes: An urgent need
Saboo, B., Kesavadev, J., Shankar, A., Krishna, M. B., Sheth, S., Patel, V., & Krishnan, G. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e05967 · Cited by 44
“Lack of effective diabetes education programs to support the physicians and patients in CGM data analysis and better interpretation of the TIR data is another limitation [1].”
BackgroundSelf-citationLeveraging advances in diabetes technologies in primary care: a narrative review
Bode, B. W., King, A., Russell-Jones, D. L., & Billings, L. K. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1931427 · Cited by 46
Lee, M. H., Paldus, B., Vogrin, S., Morrison, D., Zaharieva, D. P., Lu, J., Jones, H. M., Netzer, E., Robinson, L., Grosman, B., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0814 · Cited by 37
Penalty weighted glucose prediction models could lead to better clinically usage
Cichosz, S. L., Kronborg, T., Jensen, M. H., & Hejlesen, O. K. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104865 · Cited by 42
Zhu, X., Zhao, L., Chen, J., Lin, C., Lv, F., Hu, S., Cai, X., Zhang, L., & Ji, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.767152 · Cited by 50
Continuous glucose monitoring for hypoglycaemia in children: perspectives in 2020
Worth, C., Dunne, M., Ghosh, A., Harper, S., & Banerjee, I. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13029 · Cited by 37
“The Advanced Technologies and Treatments for Diabetes (ATTD) Congress devised a consensus recommendation for CGM data utilization to try to aim interpretation and standardize use.(77) The development of an auto-”
BackgroundEffect of Professional CGM (pCGM) on Glucose Management in Type 2 Diabetes Patients in Primary Care
Simonson, G. D., Bergenstal, R. M., Johnson, M. L., Davidson, J. L., & Martens, T. W. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821998724 · Cited by 37
Self-citationMo, Y., Ma, X., Lu, J., Shen, Y., Wang, Y., Zhang, L., Lu, W., Zhu, W., Bao, Y., & Zhou, J. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13453 · Cited by 39
Fung, E., Lui, L.-T., Huang, L., Cheng, K. F., Lau, G. H. W., Chung, Y. T., Ahmadabadi, B. N., Xie, S., Lee, J. S. W., Hui, E., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00251-8 · Cited by 38
Battelino, T., Danne, T., Edelman, S. V., Choudhary, P., Renard, É., Westerbacka, J., Mukherjee, B., Pilorget, V., Coudert, M., & Bergenstal, R. M. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14898 · Cited by 41
“TIR), time above range (TAR) and time below range (TBR), and glucose variability metrics such as glucose coefficient of variation (CV), which add to and complement traditional metrics such as HbA1c.(18,19) Furthermore, standard blood glucose monitoring can underestimate hypoglycaemia,(20-22) with one study in type 2 d…”
BackgroundResultInfluentialSelf-citationLiang, X., Fu, Y., Lu, S., Shuai, M., Miao, Z., Gou, W., Shen, L., Liang, Y., Xu, F., Tian, Y., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100823 · Cited by 72
“For our primary analyses, we performed logistic regression analysis to estimate the odds ratio (OR, 95% con fi dence intervals [CI]) of any adverse pregnancy outcome per SD change in each of the CGM-derived biomarker (i.e., TIR, TAR, TBR, AUC, nighttime MBG, daytime MBG, daily MBG, MAGE, and CV), with model 1 as crude…”
MethodInfluentialPetrovski, G., Campbell, J., Pasha, M., Hussain, K., Khalifa, A., Umer, F., Almajaly, D., Hamdar, M., van den Heuvel, T. R. A., & Edd, S. N. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0429 · Cited by 45
“22 In the present study, 94% of participants used the optimal settings (glucose target of 100 mg/dL and active insulin time of 2 h) during the 12-month follow-up, which likely contributed to the high glycemic outcomes.”
Cichosz, S. L., Kronborg, T., Laugesen, E., Hangaard, S., Fleischer, J., Hansen, T. K., Jensen, M. H., Poulsen, P. L., & Vestergaard, P. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0226 · Cited by 223
“Among the metrics assessed were the time spent within speci fi c glycemic ranges, including time in range (TIR) 26,28 between 70 – 180 mg/dL, time below range (TBR1) 26,28 between 54 – 69 mg/dL, time below range (TBR2) 26,28 below 54 mg/dL, time above range (TAR1) 26,28 between 181 – 250 mg/dL, and time above range (TA…”
InfluentialDiagnosis, Therapy and Follow-up of Diabetes Mellitus in Children and Adolescents
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0869-0210 · Cited by 39
“[43] Battelino T, Danne T, Bergenstal RM et al.”
BackgroundSelf-citationMalecki, M. T., Cao, D., Liu, R., Hardy, T., Bode, B., Bergenstal, R. M., & Bue-Valleskey, J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0129 · Cited by 36
“12 In a large study of patients with type 1 diabetes and type 2 diabetes ( n = 1200), Heller et al. found that increased severity and frequency of acute postprandial hyperglycemia is associated with greater burden and experience of symptoms and can negatively impact daily functioning of patients.”
Self-citationKuroda, N., Kusunoki, Y., Osugi, K., Ohigashi, M., Azuma, D., Ikeda, H., Makino, S., Otsuka, A., Tamada, D., Watanabe, N., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13336 · Cited by 43
Glucose variability and mood in adults with diabetes: A systematic review
Muijs, L. T., Racca, C., de Wit, M., Brouwer, A., Wieringa, T. H., de Vries, R., Serné, E. H., van Raalte, D. H., Rutters, F., & Snoek, F. J. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.152 · Cited by 43
“Penckofer 2012 Primary Observational 72 h USA 23 100 Median 51 (40-67) 2 10 (2-26) NR Median 8.”
Kerr, D. E., Barua, S., GLANTZ, N. M., Conneely, C., KUJAN, M. A., Bevier, W. C., LAREZ, A. J., & Sabharwal, A. (2020) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2020-000133 · Cited by 37
Sofizadeh, S., Pehrsson, A., Ólafsdóttir, A. F., & Lind, M. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820965599 · Cited by 38
Jeyaventhan, R., Gallen, G., Choudhary, P., & Hussain, S. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14439 · Cited by 36
Bode, B. W., Carlson, A. L., Liu, R., Hardy, T. A., Bergenstal, R. M., Boyd, J., Morrett, S., & Ignaut, D. A. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0184 · Cited by 38
Self-citationGarofolo, M., Aragona, M., Rodia, C., Falcetta, P., Bertolotto, A., Campi, F., Prato, S. D., & Penno, G. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109066 · Cited by 37
“[8] Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al.”
Bisio, A., Anderson, S. M., Norlander, L., O’Malley, G., Robic, J., OGYAADU, S. J., Hsu, L. J., Levister, C. M., Ekhlaspour, L., Lam, D. W.-H., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0838 · Cited by 41
Self-citationPAULEY, M. E., Tommerdahl, K. L., Snell‐Bergeon, J. K., & Forlenza, G. P. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01799-x · Cited by 46
Addala, A., Ding, V. Y., Zaharieva, D. P., Bishop, F. K., Adams, A. S., King, A. C., Johari, R., Scheinker, D., Hood, K. K., Desai, M., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.8881 · Cited by 41
Dunn, T. C., Xu, Y., Bergenstal, R. M., Ogawa, W., & Ajjan, R. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0146 · Cited by 47
“55 It can be argued that with the widespread use of CGM, reliance will shift from HbA1c to normalizing glucose levels.”
Self-citationTowards Wearable-based Hypoglycemia Detection and Warning in Diabetes
Maritsch, M., Föll, S., Lehmann, V., Bérubé, C., Kraus, M., Feuerriegel, S., Kowatsch, T., Züger, T., Stettler, C., Fleisch, E., et al. (2020) · Extended Abstracts of the 2020 CHI Conference on Human Factors in Computing Systems · doi:10.1145/3334480.3382808 · Cited by 35
Kusinski, L. C., Murphy, H. R., Rolfe, E. D. L., Rennie, K. L., Griep, L. M. O., Hughes, D. J., Taylor, R., & Meek, C. L. (2020) · Nutrients · doi:10.3390/nu12041165 · Cited by 44
“Maternal outcomes at 32 weeks, 36 weeks and postpartum: Maternal outcomes to be studied include maternal weight, BMI, glycaemia (CGM metrics as per the international consensus recommendations [35], HbA1c), cardiometabolic health (blood pressure, lipids, fasting insulin, fasting glucose), maternal food choice and eatin…”
MethodSelf-citationTaya, N., Katakami, N., Mita, T., Okada, Y., Wakasugi, S., Yoshii, H., Shiraiwa, T., Otsuka, A., Umayahara, Y., Ryomoto, K., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01288-5 · Cited by 36
“TIR, TAR, and TBR were recommended as standardized CGM metrics in the International Conference on Advanced Technologies and Treatments for Diabetes 2019 [33].”
MethodMCVEAN, J. J. F., & Miller, J. D. (2021) · Expert Review of Medical Devices · doi:10.1080/17434440.2021.1926984 · Cited by 41
“Initial recommendations are for PWD to spend >70% of the time between 70 and 180 mg/dL (3.9–10 mmol/L) and 25% of the time over 180 mg/dL (10 mmol/L) defined as Time Above Range (TAR) [22].”
BackgroundInfluentialA Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes
Bassi, M., Teliti, M., Lezzi, M., Iosca, A., Strati, M. F., Carmisciano, L., d’Annunzio, G., Minuto, N., & Maggi, D. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.802419 · Cited by 41
“In both cases adherence to the sensor use was adequate (> 85%) (9, 24, 25).”
BackgroundCzupryniak, L., Dzida, G. J., Fichna, P., Jarosz-Chobot, P. A., Gumprecht, J., Klupa, T., Myśliwiec, M., Szadkowska, A., Bomba-Opon, D. A., Czajkowski, K., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01229-9 · Cited by 44
“1), the AGP report consists of three sections: (1) glucose statistics and targets; (2) the ambulatory glucose profile; and (3) daily glucose profiles [6].”
BackgroundMethodInfluentialNg, S. M., Katkat, N., Day, H., Hubbard, R. A., Quinn, M., & Finnigan, L. (2022) · Diabetic Medicine · doi:10.1111/dme.14863 · Cited by 41
Valenzano, M., Cibrario Bertolotti, I., Valenzano, A., & Grassi, G. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001045 · Cited by 34
“…the procedures to calibrate their sensors and upload CGM data (in the case they were requested to do so themselves, in particular with rtCGM sensors) during a preliminary visit and a subsequent 2-week training, and then CGM was started and data seamlessly collected for a full 1-year time period.”
InfluentialReznik, Y., Carvalho, M., Fendri, S., Prevost, G., Chaillous, L., Riveline, J. P., Hanaire, H., Dubois, S., Houéto, P., Pasche, H., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15351 · Cited by 34
Benhamou, P., Adenis, A., Lebbad, H., Tourki, Y., Heredia, M., Gehr, B., Franc, S., & Charpentier, G. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15008 · Cited by 35
“In this retrospective analysis, we looked at the glucose metrics among the FAS population, as defined by the International Consensus on Use of Continuous Glucose Monitoring.(9,10) The primary endpoint was the percentage of time spent in the glucose range of 70-180 mg/dl (TIR).”
MethodZelada, H., Perez‐Guzman, M. C., Cherñavvsky, D. R., & Galindo, R. J. (2023) · Endocrine Connections · doi:10.1530/ec-23-0180 · Cited by 36
“While there are established guidelines for CGM metrics and targets for clinical care in the ambulatory setting (53), there is a need for standardized recommendations on what CGM metrics and glucose targets are appropriate for the hospital setting (30).”
Background
Metadata
- Authors
- Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
- Affiliations
- University of Ljubljana (SI)
- Kinderkrankenhaus auf der Bult (DE)
- Park Nicollet Health Services (US)
- King's College London (GB)
- Jaeb Center for Health Research (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- American Diabetes Association (US)
- Close Concerns (United States) (US)
- University of Padua (IT)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Sydney (AU)
- Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
- University of Colorado Denver (US)
- Grunberger Diabetes Institute (US)
- University of Sheffield (GB)
- Science Consulting in Diabetes, Neuss, Germany
- University of Washington (US)
- University of Cambridge (GB)
- Shanghai Jiao Tong University (CN)
- University of Virginia (US)
- Breakthrough T1D (US)
- Joslin Diabetes Center (US)
- Endocrinology Research Center (RU)
- KU Leuven (BE)
- University of East Anglia (GB)
- Schneider Children's Medical Center (IL)
- Steno Diabetes Center Copenhagen (DK)
- CGParkin Communications, Inc., Henderson, NV
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
- Biomedical Informatics Consultants LLC, Potomac, MD
- DiaCare, Ahmedabad, Gujarat, India
- University of Florida (US)
- dQ&A Market Research, Inc., San Francisco, CA
- Nihon University (JP)
- Yale University (US)
- Tel Aviv University (IL)
- Corresponding author
- Battelino, Tadej
- ORCID
- Battelino, Tadej
- Danne, Thomas
- Bergenstal, Richard M.
- Amiel, Stephanie A.
- Beck, Roy
- Biester, Torben
- Bosi, Emanuele
- Buckingham, Bruce A.
- Cefalu, William T.
- Close, Kelly L.
- Cobelli, Claudio
- Dassau, Eyal
- DeVries, J. Hans
- Donaghue, Kim C.
- Doyle, Francis J.
- Garg, Satish
- Grunberger, George
- Heller, Simon
- Heinemann, Lutz
- Hirsch, Irl B.
- Hovorka, Roman
- Jia, Weiping
- Kordonouri, Olga
- Kovatchev, Boris
- Kowalski, Aaron
- Laffel, Lori
- Levine, Brian
- Mayorov, Alexander
- Mathieu, Chantal
- Murphy, Helen R.
- Nimri, Revital
- Nørgaard, Kirsten
- Parkin, Christopher G.
- Renard, Eric
- Rodbard, David
- Saboo, Banshi
- Schatz, Desmond
- Stoner, Keaton
- Urakami, Tatsuiko
- Weinzimer, Stuart A.
- Phillip, Moshe
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1593-1603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973648
- OpenAlex
- W2948261890
- Cited by
- 4,237
- References
- 96
- Citations by year
- 2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
- FWCI
- 215.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Insulet Corporation
- MannKind Corporation
- Dexcom
- OPKO Health
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
- Universiteit van Amsterdam
- KU Leuven
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- Abbott Diabetes Care
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
- MeSH terms
- Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.